Aged 5 years to less than 12 years at Visit 1. At least 15 (25%) children of the total study population must be aged 5 to less than 8 years. 
Male or pre-menarchial female subjects. 
Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1). 
Normal range for their height and weight. Weight and height measurements should fall within the percentile range 3-97% of normal values for age according to Danish growth charts. 
Have a documented diagnosis of persistent asthma, as defined by the National Institutes of Health for at least 3 months prior to the Screening Visit. 
A pre-bronchodilatory forced expiratory flow in 1 second (FEV1) at Visit 1 (Screening) >=80% predicted. There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement. 
Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose). There must be no ICS use within 2 weeks of Visit 1 (Screening). 
Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study. 
Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement. The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC). (2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis. (3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call. 

NCT02502734_inc_T1
Person
Aged
NCT02502734_inc_T2
Value
5 years to less than 12 years
NCT02502734_inc_T3
Temporal
at Visit 1
NCT02502734_inc_T4
Reference_point
Visit 1
NCT02502734_inc_T6
Person
Male
NCT02502734_inc_T7
Person
pre-menarchial
NCT02502734_inc_T8
Person
female
NCT02502734_inc_T9
Scope
pre-menarchial female
NCT02502734_inc_T10
Person
pre-adolescent
NCT02502734_inc_T11
Condition
signs of puberty
NCT02502734_inc_T12
Negation
without any
NCT02502734_inc_T13
Measurement
Tanner Stage
NCT02502734_inc_T14
Value
1
NCT02502734_inc_T15
Scope
without any signs of puberty
NCT02502734_inc_T16
Measurement
height
NCT02502734_inc_T17
Value
Normal range
NCT02502734_inc_T18
Measurement
weight
NCT02502734_inc_T19
Measurement
Weight
NCT02502734_inc_T21
Measurement
height
NCT02502734_inc_T22
Value
within the percentile range 3-97%
NCT02502734_inc_T20
Condition
persistent asthma
NCT02502734_inc_T23
Qualifier
as defined by the National Institutes of Health
NCT02502734_inc_T24
Temporal
at least 3 months prior to the Screening Visit
NCT02502734_inc_T25
Reference_point
Screening Visit
NCT02502734_inc_T26
Qualifier
pre-bronchodilatory
NCT02502734_inc_T27
Measurement
forced expiratory flow in 1 second (FEV1)
NCT02502734_inc_T28
Temporal
at Visit 1 (Screening)
NCT02502734_inc_T29
Reference_point
Visit 1 (Screening)
NCT02502734_inc_T30
Value
>=80% predicted
NCT02502734_inc_T31
Drug
Short acting beta-agonist (SABA)
NCT02502734_inc_T32
Temporal
within 4 hours of this measurement
NCT02502734_inc_T33
Reference_point
this measurement
NCT02502734_inc_T34
Negation
no
NCT02502734_inc_T35
Procedure
asthma therapies
NCT02502734_inc_T36
Temporal
prior to entry into the study
NCT02502734_inc_T37
Reference_point
entry into the study
NCT02502734_inc_T38
Drug
SABA inhaler
NCT02502734_inc_T39
Drug
salbutamol
NCT02502734_inc_T40
Drug
leukotriene receptor antagonists
NCT02502734_inc_T41
Drug
cromones
NCT02502734_inc_T42
Drug
ICS
NCT02502734_inc_T43
Drug
budesonide
NCT02502734_inc_T44
Value
<=400 micrograms (mcg)
NCT02502734_inc_T45
Scope
SABA inhaler alone (e.g. salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g. cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose)
NCT02502734_inc_T46
Procedure
ICS
NCT02502734_inc_T47
Negation
no
NCT02502734_inc_T48
Temporal
within 2 weeks of Visit 1 (Screening)
NCT02502734_inc_T49
Reference_point
Visit 1 (Screening)
NCT02502734_inc_T50
Drug
SABA
NCT02502734_inc_T51
Drug
rescue SABA